论文部分内容阅读
又名:α-F-araAMP;NSC-312887,化学名9-β-D阿拉伯糖呋喃-2-氟腺嘌呤5’-二氢磷酸盐’[CAS-75607-67-9]、美国专利号4357324.本品是由美国伯明翰南方研究所合成的抗代谢药(代号:AL35205),并由Triton Biosciences公司获得许可证。以美国国立癌症研究所为主完成了慢性淋巴性白血病(CLL)的Ⅲ期临床试验,新药应用部门已向美国提出注册申请,并计划在1989年底的适当时候向加拿大提出申请。美国已同意该药用于治疗慢性淋巴细胞性白血病和非何杰金氏淋巴瘤。约定1989年临床试验用口服制剂。对以前曾经治疗过的76例慢性淋巴细胞性
Also known as: alpha-F-araAMP; NSC-312887, chemical name 9-beta-D arabinofuranosyl-2-fluoroadenine 5’-dihydrogenphosphate [CAS-75607-67-9], US Patent No. 4357324. This product is an antimetabolite (Code: AL35205) synthesized by the Southern Institute of Birmingham, USA, and is licensed by Triton Biosciences. Completed Phase III clinical trial of chronic lymphatic leukemia (CLL) with the National Cancer Institute. The new drug application department has submitted a registration application to the United States and plans to apply to Canada at the appropriate time in late 1989. The United States has agreed to use the drug for the treatment of chronic lymphocytic leukemia and non-Hodgkin’s lymphoma. Conventional 1989 clinical trials with oral preparations. Of the 76 previously treated chronic lymphocytic